Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141)

Robert Jeraj, PhD, Fenghai Duan, PhD, Ryan J. Mattison, MD, Lale Kostakoglu, MD MPH, Daniel A. Arber, MD, Elisabeth Paietta, PhD, Justin Romanoff, AM, Jennifer Holter-Chakrabarty, MD, Charles Arnold, MD, Stephen A. Strickland, MD, Jennifer Whisenant, PhD, Barry Alan Siegel, MD, Geoffrey L Uy, MD, Kebede H. Begna, MD, Gregory Wiseman, MD, Aric C. Hall, MD, Scott Perlman, MD, Mark Litzow, MD, David Mankoff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136721

Published: 2020

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma

Anthony Q Pham, MD, Stephen Broski, Thomas M. Habermann, MD, Dragan Jevremovic, MDPhD, Gregory Wiseman, MD, Andrew L Feldman, MD, Matthew J Maurer, MS, Kay Ristow, Thomas E. Witzig, MD

Blood (2015) 126 (23): 3947.

https://doi.org/10.1182/blood.V126.23.3947.3947

Published: 2015

Journal Articles

Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience

Brian L. Burnette, MD, Gregory Wiseman, MD, Thomas M. Habermann, MD, William R Macon, MD, Stephen M. Ansell, MD, PhD, David James Inwards, MD, Ivana N. Micallef, MD, Patrick B. Johnston, Kay M. Ristow, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2011) 118 (21): 1572.

https://doi.org/10.1182/blood.V118.21.1572.1572

Published: 2011

Journal Articles

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

Brian L. Burnette, MD, Gregory Wiseman, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD, PhD, Luis F. Porrata, MD, David James Inwards, MD, Patrick B. Johnston, Ivana Micallef, William R Macon, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski

Blood (2011) 118 (21): 1640.

https://doi.org/10.1182/blood.V118.21.1640.1640

Published: 2011

Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD

Blood (2011) 118 (21): 1648.

https://doi.org/10.1182/blood.V118.21.1648.1648

Published: 2011

Journal Articles

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

Ivana N. Micallef, MD, Matthew J. Maurer, Thomas E. Witzig, MD, Daniel Nikcevich, MD, PhD, Paul Kurtin, MD, Michael W. Cannon, MD, Patrick J. Flynn, MD, Gamini S. Soori, MD, Val Lowe, MD, Gregory Wiseman, MD

Blood (2009) 114 (22): 137.

https://doi.org/10.1182/blood.V114.22.137.137

Published: 2009

Journal Articles

Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404

Sandra J. Horning, MD, Malik E. Juweid, MD, Heiko Schoder, Gregory Wiseman, MD, Alex McMillan, Ph.D., Lode J. Swinnen, MBChB, Ranjana Advani, MD, Randy D. Gascoyne, MD, Andrew Quon

Blood (2008) 112 (11): 372.

https://doi.org/10.1182/blood.V112.11.372.372

Published: 2008

Journal Articles

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

George Weiner, MD, Gregory Wiseman, MD, Thomas Witzig, MD, Brian Link, MD, James Wooldridge, MD, James Ponto, MD, Malik Juweid, MD

Blood (2005) 106 (11): 2823.

https://doi.org/10.1182/blood.V106.11.2823.2823

Published: 2005

Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD

Blood (2004) 104 (11): 2634.

https://doi.org/10.1182/blood.V104.11.2634.2634

Published: 2004

NARROW

Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141)

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma

Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only